Biomarker ID | 1879 |
PMID | 30446464 |
Year | 2018 |
Biomarker | Testosterone |
Biomarker Basis | Concentration Based (ng/mL) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Decreased in Biochemical Recurrence Free Survival |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.35 |
Effect on Pathways | NA |
Experiment | Progression Free Survival Vs No Progression Free Survival |
Type of Biomarker | Prognostic |
Cohort | 106 Japanese patients were selected for the study. 35 patients were treated with Enzalutamide and selected for this analysis. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.037 |
Method Used | electrochemiluminescence immunoassay |
Clinical | No |
Remarks | Progression was defined according to consecutive PSA increments resulting in 25% increases and 2 ng/ml over the nadir despite consecutive ADT, or progression of soft-tissue lesions or appearance of 2 lesions on a bone scan . Only patients treated with Enzalutamide were selected for this |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |